자폐를 위한 분변 이식, 임상시험에서 성공을 거두다 (2019)

This research demonstrates that fecal microbiota transplantation reduces autism symptoms by 45% and downgrades 83% of severe cases to mild or subclinical status—validating the gut-brain axis as a therapeutic target. The sustained improvements over two years indicate that addressing microbiome diversity can treat both gastrointestinal dysfunction and behavioral symptoms simultaneously, representing a paradigm shift from purely neurological models. As Microbiota Transplant Therapy advances to Phase 3 trials with FDA approval anticipated, this breakthrough could offer the first microbiome-based treatment for the 1 in 59 children diagnosed with autism.